Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 2/20 | 0.32 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.31 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.31 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.30 |
| ▸ | MAPKAPK5 | Q8IW41 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8246540 | 0.77 | AURKA (0.54) | AURKAPTK6AURKBMAPKAPK5 | |
| SCHEMBL8426788 | 0.75 | AURKA (0.35) | AURKAADORA3MAPKAPK5 | |
| SCHEMBL14534281 | 0.74 | LRRK2 (0.40) | — | |
| SCHEMBL12473231 | 0.74 | AURKA (0.34) | AURKAADORA3AURKBMAPKAPK5 | |
| SCHEMBL8427741 | 0.74 | BRD4 (0.39) | ADORA3 | |
| SCHEMBL14533855 | 0.73 | MAPK1 (0.38) | — | |
| SCHEMBL8429587 | 0.72 | ADORA3 (0.38) | AURKAPTK6ADORA3AURKBMAPKAPK5 | |
| SCHEMBL8426757 | 0.71 | CHRNB2 (0.37) | AURKAADORA3AURKB | |
| SCHEMBL8427744 | 0.71 | MAPKAPK5 (0.38) | AURKAPTK6ADORA3MAPKAPK5 | |
| SCHEMBL8429895 | 0.71 | PAK4 (0.42) | AURKAPTK6ADORA3AURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7576085-B2 | Imidazopyrazines as cyclin dependent kinase inhibitors | SCHERING CORPORATION (US) | 2009-08-18 | — | — | US | disclosed |
| US-20060106023-A1 | Novel imidazopyrazines as cyclin dependent kinase inhibitors | SCHERING CORPORATION | 2006-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106023-A1 | Novel imidazopyrazines as cyclin dependent kinase inhibitors | CDK2, CDKN1A, CDK1 | AURKA 91/4885PTK6 692/4885ADORA3 3961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.